Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer

BACKGROUND: Nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/levo-leucovorin (Levo-LV) was approved for unresectable pancreatic cancer (UR-PC) in March 2020 in Japan. Levo-LV is administered by intravenous infusion over 120 min following 90 min intravenous infusion of nal-IRI (conventio...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, Ryoji, Ikezawa, Kenji, Yamai, Takuo, Watsuji, Ko, Seiki, Yusuke, Kawamoto, Yasuharu, Hirao, Takeru, Higashi, Sena, Urabe, Makiko, Kai, Yugo, Nakabori, Tasuku, Uehara, Hiroyuki, Kotani, Michiyo, Yagi, Toshinari, Kimura, Miho, Nozaki, Keisuke, Takagi, Mari, Ohkawa, Kazuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388465/
https://www.ncbi.nlm.nih.gov/pubmed/37518012
http://dx.doi.org/10.1186/s12885-023-11205-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388465/
https://www.ncbi.nlm.nih.gov/pubmed/37518012
http://dx.doi.org/10.1186/s12885-023-11205-6

Ejemplares similares